Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer? Request More Information Trial Objective The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC). Enrollment Active Clinical Trials Currently Recruiting Who Can Participate You may be able to join this study if you are at least 18 years old, with medically inoperable Stage I/IIA NSCLC and if you have not received prior anticancer therapy for lung cancer. Age: 18+ Gender: Any Gender Estimated Time Commitment Up to 7 years If you are eligible and choose to be in the study, your participation will last up to 7 years. You will be asked to visit the study site about 26 times. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Not Provided Travel Reimbursement: Available Trial Contact For more information, contact: Jami Henriksen 303.398.1233 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Merck Sharp & Dohme Corp. Principal Investigators Laurie Carr, MD + × Laurie Carr, MD Associate Professor Department of Medicine Division of Oncology, Cancer Center View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Co-Investigators Jeffrey Kern, MD + × Jeffrey Kern, MD Chief, Division of Oncology, Cancer Center Director, Lung Cancer Center Vice Chair, Finance Professor Department of Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).